Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey.
Li-Fraumeni syndrome
adherence
hereditary breast cancer
pathogenic TP53 germline variant
surveillance
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
received:
05
02
2020
revised:
06
04
2020
accepted:
04
05
2020
pubmed:
20
6
2020
medline:
22
5
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
Li-Fraumeni syndrome (LFS) is a high-risk cancer predisposition syndrome caused by pathogenic germline variants of TP53. Cancer surveillance has noted a significant survival advantage in individuals with LFS; however, little is known about the feasibility, acceptance, and psychosocial effects of such a program. Pathogenic TP53 germline variant carriers completed a 7-part questionnaire evaluating sociodemographics, cancer history, surveillance participation, reasons for nonadherence, worries, and distress adapted from the Cancer Worry Scale. Counselees' common concerns and suggestions were assessed in MAXQDA Analytics Pro 12. Forty-nine participants (46 females and 3 males), aged 40.0 ± 12.6 years, formed the study population; 43 (88%) had a personal cancer history (including multiple cancers in 10 [20%]). Forty-three individuals participated (88%) in surveillance during the study or formerly. Willingness to undergo surveillance was influenced by satisfaction with genetic testing and counseling (P = .019 [Fisher-Yates test]) but not by sociodemographics, cancer history, or distress level. Almost one-third of the participants reported logistical difficulties in implementing surveillance because of the high frequency of medical visits, scheduling difficulties, and the travel distance to their surveillance providers. Self-reported distress and perceived emotional burden for family members and partners were moderate (median for self-reported distress, 3.3; median for perceived emotional burden, 3.0). For both, the interquartile range was moderate to very high (2.7-3.7 and 3.0-3.7, respectively). Individuals with LFS require efficient counseling as well as an accessible, well-organized, interdisciplinary, standardized surveillance program to increase adherence and psychological coping.
Sections du résumé
BACKGROUND
Li-Fraumeni syndrome (LFS) is a high-risk cancer predisposition syndrome caused by pathogenic germline variants of TP53. Cancer surveillance has noted a significant survival advantage in individuals with LFS; however, little is known about the feasibility, acceptance, and psychosocial effects of such a program.
METHODS
Pathogenic TP53 germline variant carriers completed a 7-part questionnaire evaluating sociodemographics, cancer history, surveillance participation, reasons for nonadherence, worries, and distress adapted from the Cancer Worry Scale. Counselees' common concerns and suggestions were assessed in MAXQDA Analytics Pro 12.
RESULTS
Forty-nine participants (46 females and 3 males), aged 40.0 ± 12.6 years, formed the study population; 43 (88%) had a personal cancer history (including multiple cancers in 10 [20%]). Forty-three individuals participated (88%) in surveillance during the study or formerly. Willingness to undergo surveillance was influenced by satisfaction with genetic testing and counseling (P = .019 [Fisher-Yates test]) but not by sociodemographics, cancer history, or distress level. Almost one-third of the participants reported logistical difficulties in implementing surveillance because of the high frequency of medical visits, scheduling difficulties, and the travel distance to their surveillance providers. Self-reported distress and perceived emotional burden for family members and partners were moderate (median for self-reported distress, 3.3; median for perceived emotional burden, 3.0). For both, the interquartile range was moderate to very high (2.7-3.7 and 3.0-3.7, respectively).
CONCLUSIONS
Individuals with LFS require efficient counseling as well as an accessible, well-organized, interdisciplinary, standardized surveillance program to increase adherence and psychological coping.
Substances chimiques
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4032-4041Informations de copyright
© 2020 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33:2345-2352.
Lustbader ED, Williams WR, Bondy ML, Strom S, Strong LC. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet. 1992;51:344-356.
Mai PL, Best AF, Peters JA, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122:3673-3681.
Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 2016;17:1295-1305.
Kratz CP, Achatz MI, Brugieres L, et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res. 2017;23:e38-e45.
Deutsches Konsortium Familiärer Brust- und Eierstockkrebs. Konsensusempfehlung zum Umgang mit Ergebnissen der Multigenanalyse. Accessed June 1, 2020. https://www.konsortium-familiaerer-brustkrebs.de/konsensusempfehlung/
Schneider K, Zelley K, Nichols KE, Garber J. Li-Fraumeni syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews. University of Washington; 1993- 2020.
Waha A, Versmold B, Kast K, et al. Konsensusempfehlung des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs zum Umgang mit Ergebnissen der Multigenanalyse. Tumordiagn Ther. 2018;39:187-193. doi:10.1055/a-0574-4879
Bojadzieva J, Amini B, Day SF, et al. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic. Fam Cancer. 2018;17:287-294.
Ballinger ML, Best A, Mai PL, et al. Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncol. 2017;3:1634-1639.
Ballinger ML, Ferris NJ, Moodie K, et al. Surveillance in germline TP53 mutation carriers utilizing whole-body magnetic resonance imaging. JAMA Oncol. 2017;3:1735-1736.
Mai PL, Khincha PP, Loud JT, et al. Prevalence of cancer at baseline screening in the National Cancer Institute Li-Fraumeni syndrome cohort. JAMA Oncol. 2017;3:1640-1645.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-424.
Deutsches Konsortium Familiärer Brust- und Eierstockkrebs. Erkennung von Genveränderungen durch einen Gentest. Accessed June 1, 2020. https://www.konsortium-familiaerer-brustkrebs.de/informationen/gentest-einschlusskriterien/
Hauke J, Horvath J, Gross E, et al. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancer Med. 2018;7:1349-1358.
Deutsches Konsortium Familiärer Brust- und Eierstockkrebs. Die TruRisk Gen-Analyse bei familiärem Brust- und Eierstockkrebs. Accessed June 1, 2020. https://www.konsortium-familiaerer-brustkrebs.de/molekulare-diagnostik/trurisk-gen-analyse/
Vetter L, Keller M, Bruckner T, et al. Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany. Breast Cancer Res Treat. 2016;156:289-299.
Keller M, Jost R, Haunstetter CM, et al. Psychosocial outcome following genetic risk counselling for familial colorectal cancer. A comparison of affected patients and family members. Clin Genet. 2008;74:414-424.
Keller M, Sommerfeldt S, Fischer C, et al. Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach. Ann Oncol. 2004;15:1243-1249.
Eismann S, Vetter L, Keller M, et al. Long-term experiences with genetic consultation in people with hereditary breast and ovarian cancer. Arch Gynecol Obstet. 2016;294:1011-1018.
Schott S, Vetter L, Keller M, et al. Women at familial risk of breast cancer electing for prophylactic mastectomy: frequencies, procedures, and decision-making characteristics. Arch Gynecol Obstet. 2017;295:1451-1458.
Lerman C, Kash K, Stefanek M. Younger women at increased risk for breast cancer: perceived risk, psychological well-being, and surveillance behavior. J Natl Cancer Inst Monogr. 1994;16:171-176.
Hopwood P, Shenton A, Lalloo F, Evans DG, Howell A. Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer. J Med Genet. 2001;38:139.
Codori AM, Petersen GM, Miglioretti DL, et al. Attitudes toward colon cancer gene testing: factors predicting test uptake. Cancer Epidemiol Biomarkers Prev. 1999;8(4 pt 2):345-351.
Vernon SW, Gritz ER, Peterson SK, et al. Intention to learn results of genetic testing for hereditary colon cancer. Cancer Epidemiol Biomarkers Prev. 1999;8(4 pt 2):353-360.
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77-101.
Kuckartz U. Qualitative Text Analysis: A Guide to Methods, Practice & Using Software. Sage; 2014.
Lammens CR, Bleiker EM, Aaronson NK, et al. Regular surveillance for Li-Fraumeni syndrome: advice, adherence and perceived benefits. Fam Cancer. 2010;9:647-654.
Bancroft EK, Saya S, Brown E, et al. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY). J Med Genet. 2020;57:226-236.
McBride KA, Ballinger ML, Schlub TE, et al. Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? Fam Cancer. 2017;16:423-432.
Gopie JP, Vasen HF, Tibben A. Surveillance for hereditary cancer: does the benefit outweigh the psychological burden?-a systematic review. Crit Rev Oncol Hematol. 2012;83:329-340.
Pantaleao A, Young JL, Epstein NB, et al. Family health leaders: lessons on living with Li-Fraumeni syndrome across generations. Fam Process. Published online October 24, 2019. doi:10.1111/famp.12497
Bakhuizen JJ, Velthuizen ME, Stehouwer S, Bleiker EM, Ausems MG. Genetic counselling of young women with breast cancer for Li-Fraumeni syndrome: a nationwide survey on the experiences and attitudes of genetics professionals. Fam Cancer. 2019;18:231-239.
Chompret A, Brugieres L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000;82:1932-1937.
Hwang SJ, Lozano G, Amos CI, Strong LC. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet. 2003;72:975-983.
Wu CC, Shete S, Amos CI, Strong LC. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. Cancer Res. 2006;66:8287-8292.
Lammens CR, Aaronson NK, Wagner A, et al. Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences. J Clin Oncol. 2010;28:3008-3014.
Peterson SK, Pentz RD, Marani SK, et al. Psychological functioning in persons considering genetic counseling and testing for Li-Fraumeni syndrome. Psychooncology. 2008;17:783-789.
Oppenheim D, Brugieres L, Chompret A, Hartmann O. The psychological burden inflicted by multiple cancers in Li-Fraumeni families: five case studies. J Genet Couns. 2001;10:169-183.
van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, et al. Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing. Ann Oncol. 2006;17:1090-1095.
Wellisch DK, Gritz ER, Schain W, Wang HJ, Siau J. Psychological functioning of daughters of breast cancer patients: part II: characterizing the distressed daughter of the breast cancer patient. Psychosomatics. 1992;33:171-179.
Wellisch DK, Hoffman A. Daughters of breast cancer patients. In: Danieli Y, ed. International Handbook of Multigenerational Legacies of Trauma. Springer; 1998:603-619.
Inhestern L, Bultmann JC, Beierlein V, et al. Psychometric properties of the Parenting Concerns Questionnaire in cancer survivors with minor and young adult children. Psychooncology. 2016;25:1092-1098.
Young JL, Pantaleao A, Zaspel L, et al. Couples coping with screening burden and diagnostic uncertainty in Li-Fraumeni syndrome: connection versus independence. J Psychosoc Oncol. 2019;37:178-193.